6 completed, 2 no longer available, 2 terminated, 1 not yet recruiting. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Not yet recruiting 1 |
| Phase 1 | 4 | Completed 2, Not yet recruiting 1, Withdrawn 1 |
Follow NanOlogy, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response LSAM-Cisplatin - Diffuse Midline Glioma (DMG), Diffuse Intrinsic Pontine Glioma (DIPG) | Phase 1 / Phase 2 | Not yet recruiting | NanOlogy, LLC | 20 | 2026-12-01 | 2026-08-18 |
| Trial of NanoPac Intratumoral Injection in Lung Cancer NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension - Lung Cancer, Nonsmall Cell, Lung Cancer | Phase 2 | Completed | NanOlogy, LLC | 18 | 2021-04-14 | 2025-05-23 |
| Trial of NanoPac Focal Therapy for Prostate Cancer NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Terminated | NanOlogy, LLC | 1 | 2020-10-20 | 2022-03-29 |
| Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension - Renal Cell Carcinoma, Kidney Cancer | Phase 1 | Withdrawn | NanOlogy, LLC | 2020-04-01 | 2020-08-04 | |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care - Bladder Cancer, Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | NanOlogy, LLC | 36 | 2019-04-02 | 2023-08-14 |
| Study of Topical SOR007 Ointment for Cutaneous Metastases SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment - Cutaneous Metastasis | Phase 1 / Phase 2 | Completed | NanOlogy, LLC | 23 | 2018-01-31 | 2021-11-05 |
| Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma NanoPac® - Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Completed | NanOlogy, LLC | 54 | 2017-12-01 | 2024-06-24 |
| Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms NanoPac® - Pancreatic Mucinous-Cystic Neoplasm | Phase 2 | Completed | NanOlogy, LLC | 20 | 2017-09-29 | 2021-06-14 |
| Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer NanoPac® - Adenocarcinoma of the Prostate | Phase 2 | Completed | NanOlogy, LLC | 16 | 2017-09-06 | 2019-08-20 |
| Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer NanoPac® 100 mg/m2, NanoPac® 200 mg/m2, NanoPac® 300 mg/m2 - Ovarian Carcinoma | Phase 2 | Terminated | NanOlogy, LLC | 10 | 2017-04-19 | 2021-04-27 |
| Expanded Access to NanoDoce NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension - Urogenital Neoplasms | No longer available | NanOlogy, LLC | 2026-01-23 | |||
| Expanded Access to NanoPac NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension - Locally Advanced Pancreatic Carcinoma, Prostate Cancer | No longer available | NanOlogy, LLC | 2026-01-23 |
Urogenital Neoplasms (4) · Prostatic Neoplasms (3) · Digestive System Neoplasms (2) · Genital Neoplasms, Male (2) · Lung Neoplasms (2) · Pancreatic Diseases (2) · Pancreatic Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Diffuse Intrinsic Pontine Glioma (1) · Digestive System Diseases (1) · Kidney Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Ovarian Diseases (1)
Paclitaxel (5) · Powders (5) · Suspensions (5) · Docetaxel (3) · Administration, Intravesical (1) · Neoadjuvant Therapy (1) · Ointments (1)
United States (8)
Shelagh Verco, PhD (4) · Donald Lamm, MD, FACS (1) · Joan Walker, MD (1) · Julie E Lang, MD (1) · Rose Marie Cavanna-Mast (1) · Rose Marie Cavanna-Mast, RT, CCRA (1)